Howard University Telehealth Training Center
HUTTC Home | About | News | Current Projects | Past Projects | On-Demand Videos and Podcasts

4. Issues of Ethnopharmacology in HIV Management

Role of Delta-32 Deletion (Δ32)

Differences in the way that some individuals’ host cells express the CCR5 coreceptor are associated with differences in how susceptible a person is to becoming infected with HIV and in how rapidly disease may progress in patients who already are HIV-positive. One of the pairs of alleles (forms of the gene) that encode for the CCR5 coreceptor can occur in a mutated form, called Δ32. In persons having 2 normal copies of this allele, HIV disease progresses in the standard way. However, in persons in whom Δ32 occurs as 1 member of the pair, HIV progression is typically slower. Such individuals, who make up approximately 10% to 15% of the white population, are called heterozygous for Δ32, have fewer CCR5 molecules on their CD4+ cell surfaces, and have relatively normal immune function.[McNicholl 1997, Wu 1997] Persons who have 2 copies of Δ32, who make up approximately 1% of the white population, are called homozygous for Δ32;  they do not have CCR5 molecules on their CD4+ cell surfaces and therefore are resistant to becoming infected with strains of HIV that use the CCR5 coreceptor, although they can become infected with X4 virus.[McNicholl 1997, Liu 1996, Samson 1996]

Correlation of Δ32 with other health conditions. In addition to the correlation of the presence or absence of Δ32 with HIV disease progression, this allele has also been found to have correlations with other health conditions:[Ahlenstiel 2004]

  • Δ32 homozygous:
    • Improved renal transplant survival
    • Potential susceptibility to multiple sclerosis
    • Increased susceptibility to West Nile virus infection
  • Δ32 heterozygous:
    • Milder disease course in patients with rheumatoid arthritis
    • Delayed onset and fewer relapses in patients with multiple sclerosis
    • Increased disease severity in patients with sarcoidosis (inflammatory disease characterized by granulomatous lesions appearing in the liver, lungs, skin, and lymph nodes)
    • Increased disease severity in patients with lupus erythematosis

How CCR5 Antagonists Work

One CCR5 antagonist, maraviroc, has received US Food and Drug Administration (FDA) approval, and another remains in clinical development. Both agents bind to the CCR5 coreceptor by altering the coreceptor’s structure so that most strains of HIV cannot recognize it. [Watson 2005, Westby 2007] In the presence of a CCR5 antagonist, HIV can still bind to CD4 but it can no longer bind to CCR5, thereby eliminating the CCR5 trigger that would normally lead to membrane fusion, which then cannot occur.

Assessing Viral Tropism

The first hurdle in deciding whether and how to use a CCR5 antagonist is assessing the tropism of a patient’s HIV population. Two methods of assessing viral tropism are available: genotyping and phenotyping. [Van Baelen 2007, Jensen 2007] At this time, phenotyping continues to be the most effective method to assess coreceptor use and to guide the use of CCR5 antagonists. [Whitcomb 2007]

« BACK

NEXT »